Brief: Caplin Point says USFDA to inspect co's sterile injectable site in Tamil Nadu
Sept 9 (Reuters) - Caplin Point Laboratories Ltd CAPL.NS : * US FDA inspection is to be conducted for co's sterile injectable site located near Gummidopoondi in third week of October * Prior Approval Inspection (PAI) is in relation to an injectable product ANDA being submitted with US FDA. * Further company coverage CAPL.NS ((Bangalore.newsroom@thomsonreuters.com))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees